DOCSLIB.ORG

Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review Clinic Rev Allerg Immunol DOI 10.1007/s12016-014-8416-0 Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review Matthieu Picard & Mariana C. Castells # Springer Science+Business Media New York 2014 Abstract Taxanes (a class of chemotherapeutic agents) Keywords Taxane . Paclitaxel . Taxol . Docetaxel . are an important cause of hypersensitivity reactions Taxotere . Nab-paclitaxel . Abraxane . Cabazitaxel . (HSRs) in cancer patients. During the last decade, the Chemotherapy . Hypersensitivity . Allergy . Skin test . development of rapid drug desensitization has been key Desensitization . Challenge . Diagnosis . Review . IgE . to allow patients with HSRs to taxanes to be safely re- Complement . Mechanism treated although the mechanisms of these HSRs are not fully understood. Earlier studies suggested that solvents, such as Cremophor EL used to solubilize paclitaxel, Introduction were responsible for HSRs through complement activa- tion, but recent findings have raised the possibility that Hypersensitivity reactions (HSRs) to chemotherapy are in- some of these HSRs are IgE-mediated. Taxane skin creasingly common and represent an important impediment testing, which identifies patients with an IgE-mediated to the care of cancer patients as they may entail serious sensitivity, appears as a promising diagnostic and risk consequences and prevent patients from being treated with stratification tool in the management of patients with the most efficacious agent against their cancer [1]. During the HSRs to taxanes. The management of patients following last decade, different groups have developed rapid drug de- a HSR involves risk stratification and re-exposure could sensitization (RDD) protocols that allow the safe re- be performed either through rapid drug desensitization introduction of a chemotherapeutic agent to which a patient or graded challenge based on the severity of the initial is allergic, and their use have recently been endorsed by the HSR and the skin test result. Rapid drug desensitization National Comprehensive Cancer Network (NCCN) [2]. hasbeenshowntobeaneffectiveandsafemethodto Two classes of chemotherapeutic agents cause the vast re-introduce taxanes in hundreds of patients, including majority of chemotherapy-related HSRs: platins and taxanes those with life-threatening HSRs. Patients with non- [3]. Although it has now been well described that HSRs to severe delayed skin HSRs may benefit from rapid drug platins are IgE-mediated [4], the mechanism(s) of HSRs to desensitization since they may be at increased risk for taxanes remain to be established. This lack of a clear under- an immediate HSR upon re-exposure. This review fo- standing of what causes HSRs to taxanes has led in practice to cuses on the clinical presentation, diagnosis, and novel a greater diversity of management strategies for taxanes com- mechanisms of immediate HSRs to taxanes. A new pared with platins’ HSRs [5]. However, the possibility that an managementstrategyforHSRstotaxanesbasedonskin IgE-mediated mechanism might be implicated in some pa- testing and rapid drug desensitization is proposed. tients with HSRs to taxanes has recently been raised, and skin testing has emerged as a new diagnostic and risk stratification tool [6, 7]. Therefore, the need arose to re-visit the knowledge : acquired on HSRs to taxanes since the first use of the drug in M. Picard M. C. Castells (*) the late 1980s. Division of Rheumatology, Immunology and Allergy, Department of This review provides a general overview of the different Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1 Jimmy Fund Way, Smith Building, Boston, MA 02115, USA taxanes currently used in practice as well as a presentation of e-mail: [email protected] the different types of HSRs encountered with these agents Clinic Rev Allerg Immunol (with a focus on immediate HSRs). This is followed by a discussion of the different mechanisms that could account for these HSRs. Finally, the different strategies used in the man- agement of HSRs to taxanes (with an emphasis on rapid drug desensitization) are reviewed. Origins and Clinical Use of Taxanes Paclitaxel Paclitaxel (taxol) is a natural compound, originally isolated from the bark of the Pacific yew tree (Taxus brevifolia)inthe 1960s, with potent anticancer properties [8]. It exerts its antineoplastic effects by interfering with the dynamics of microtubules (components of the cell cytoskeleton) thereby causing mitotic block and cell death [9, 10].Taxolrarityin nature (the extraction of a single therapeutic dose necessitates the sacrifice of a 100-year-old Pacific yew tree) and its insol- ubility in water significantly hindered its development as a chemotherapeutic agent [11]. In the 1980s, a drug formulation suitable for intravenous injection was devised using Cremophor EL (polyoxyethylated castor oil), a solubilizer and emulsifying agent, and ethanol allowing clinical trials to proceed [12]. Following demonstration of its efficacy against notably ovarian and breast cancer, the need arose for a more sustainable and efficient mean of production. Total (synthetic) synthesis of paclitaxel was accomplished in 1994, but its complexity made it not commercially viable [11, 13]. A first solution came from the presence of paclitaxel precursors (10- Fig. 1 a Taxus baccata tree. b Taxus baccata needles and fruit. Pictures taken at Arnold Arboretum, Boston, MA deacetylbaccatin III and baccatin III), which can be trans- formed via a semisynthetic process into paclitaxel, in the emulsifying agent, and further diluted in an ethanol/water needles of the European yew tree (Taxus baccata)(Fig.1) solution for intravenous administration [15]. It is used in the [12]. European yew trees are more abundant than Pacific yew treatment of breast, ovarian, prostate, head and neck, and non- trees, and the needles can be harvested without killing the tree small cell lung cancers and gastric adenocarcinoma [15]. [12]. In recent years, plant cell cultures isolated from different Docetaxel is usually administered as a 1-h infusion every Taxus species and grown in large bioreactors have become the 3weeks[15]. method of choice for paclitaxel production [12]. Paclitaxel is used for the treatment of ovarian, breast, non-small cell lung cancers, and AIDS-related Kaposi’ssarcoma.Itiseitherin- Nab-Paclitaxel fused weekly, typically over 1 h, or every 3 weeks, typically over 3 h [14]. Nanoparticule albumin-bound paclitaxel (nab-paclitaxel; Abraxane) is a novel paclitaxel formulation, which does not Docetaxel contain Cremophor EL [16, 17]. It uses human serum albumin to encapsulate hydrophobic paclitaxel molecules in particles Docetaxel (taxotere) was discovered in 1986 in the search for of around 130 nm [18]. In addition, albumin is thought to a more soluble and easier to produce alternative to paclitaxel increase paclitaxel tumor uptake by, among other mecha- [12]. It was obtained from a semisynthetic process using the nisms, binding to gp60 (albondin) receptor thereby enhancing paclitaxel precursor 10-deacetylbaccatin III extracted from the the transendothelial transport of the drug [18, 19]. Abraxane needles of T. baccata [12]. Its structure is therefore highly was approved by the US FDA for the treatment of metastatic similar to paclitaxel. Despite a higher solubility than paclitax- breast cancer in 2005 and is now also approved for the el, the molecule remains insoluble in water [12]. Docetaxel is treatment of non-small cell lung cancer and adenocarcinoma formulated in polysorbate 80 (Tween 80), a solubilizer and of the pancreas [20, 21]. It is infused over 30 min and, in Clinic Rev Allerg Immunol contrast to the other taxanes, does not require the use of severe) versus 17.3 % (7.3 % severe) [34]. Also, at least one premedication to prevent HSR [21]. Many other nanoparticule death from a severe HSR has been reported in a patient delivery systems for paclitaxel are currently in development premedicated with the simplified regimen [39]. In [20]. premedicated patients, the duration of the paclitaxel infusion (3 versus 24 h) and the dose administered (175 versus 135 mg/ Cabazitaxel m2) do not influence the rate of HSRs [37, 40, 41]. Also, there is no indication that weekly paclitaxel regimens, which con- Cabazitaxel (Jevtana) is a semisynthetic taxane derived from tain lower doses and are administered as 1-h infusions, in- the precursor 10-deacetyl baccatin III contained in yew tree crease the rate of HSRs, and some groups have even success- needles that was developed to overcome tumor drug resistance fully withdrawn corticosteroid premedication in patients that to paclitaxel and docetaxel [22]. Tumor cells can overexpress had not reacted during the initial cycles [42–46]. ATP-dependant membrane transporter proteins, such as P- glycoprotein, that decrease intracellular drug concentrations Docetaxel by pumping out of the cell drugs with affinity for the trans- porter [10]. Paclitaxel and docetaxel have a high affinity for P- Several unexpected adverse events were uncovered during glycoprotein whereas cabazitaxel has a poor affinity providing phase II trials of docetaxel. A majority of patients (>50 %) the rationale for its use in certain taxane-resistant neoplasia experienced immediate HSRs that were not prevented by the [22]. Similarly to docetaxel, it is formulated in polysorbate 80 addition of premedication with antihistamines or intravenous and diluted in an ethanol/water solution before intravenous corticosteroid 30 min prior to the infusion [47–50]. Fluid
Load more

Recommended publications
  • Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L
    ISSN 2093-6966 [Print], ISSN 2234-6856 [Online] Journal of Pharmacopuncture 2019;22[2]:102-108 DOI: https://doi.org/10.3831/KPI.2019.22.013 Original article Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L. Extract and Its Potential Interaction with Doxorubicin for Esophageal Squamous Cell Carcinoma Issa Amjadi1, Mohammad Mohajeri2, Andrei Borisov3 , Motahare-Sadat Hosseini4* 1 Department of Biomedical Engineering, Wayne State University, Detroit, United States 2 Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran 3 Department of Biomedical Engineering, Wayne State University, Detroit, United States 4 Biomaterials Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran Key Words Results: Free drugs and nanoparticles significantly inhibited KYSE30 cells by 55-73% and slightly affected doxorubicin, hypericum perforatum extract, nano- normal cells up to 29%. The IC50 of Dox NPs and HP particles, esophageal squamous cell carcinoma, drug NPs was ~ 0.04-0.06 mg/mL and ~ 0.6-0.7 mg/mL, re- resistance spectively. Significant decrease occurred in cyclin D1 expression by Dox NPs and HP NPs (P < 0.05). Expo- Abstract sure of KYSE-30 cells to combined treatments includ- ing both Dox and HP extract significantly increased the Objectives: Esophageal squamous cell carcinoma level of cyclin D1 expression as compared to those with (ESCC) is considered as a deadly medical condition that individual treatments (P < 0.05). affects a growing number of people worldwide. Target- ed therapy of ESCC has been suggested recently and Conclusion: Dox NPs and HP NPs can successfully and required extensive research. With cyclin D1 as a thera- specifically target ESCC cells through downregulation peutic target, the present study aimed at evaluating the of cyclin D1.
    [Show full text]
  • Jevtana® (Cabazitaxel)
    AUSTRALIAN PRODUCT INFORMATION – JEVTANA® (CABAZITAXEL) 1 NAME OF THE MEDICINE Cabazitaxel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The concentrated solution for injection contains 60 mg cabazitaxel in 1.5 mL polysorbate 80. Diluent contains 13% w/w ethanol in 4.5 mL water for injections. Excipients of known effect: Diluent contains 13% w/w ethanol. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM The concentrated solution for injection is a clear oily yellow to brownish yellow solution. The diluent is a clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen. 4.2 DOSE AND METHOD OF ADMINISTRATION The use of Jevtana should be confined to units specialised in the administration of cytotoxics and it should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy. Premedication Premedicate at least 30 minutes prior to each administration of Jevtana with the following intravenous medications to reduce the risk and severity of a hypersensitivity reaction: jevtana-ccdsv10-piv11-10nov20 Page 1 of 26 antihistamine (equivalent to dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equivalent), corticosteroid (dexamethasone 8 mg or equivalent) and with H2 antagonist (ranitidine or equivalent). Antiemetic prophylaxis is recommended and can be given orally or intravenously as needed (see Section 4.4 Special warnings and precautions for use). Recommended Dosage The recommended dose of Jevtana is 20 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks in combination with oral prednisone (or prednisolone) 10 mg administered daily throughout Jevtana treatment.
    [Show full text]
  • Chemotherapy Protocol
    Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL (7 day) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Indication • Neoadjuvant / adjuvant therapy of early breast cancer • WHO Performance status 0, 1 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Epirubicin Cardio-toxicity, urinary discolouration (red) Hypersensitivity, hypotension, bradycardia, peripheral Paclitaxel neuropathy, myalgia and back pain on administration The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen • FBC, U&Es and LFTs prior to each cycle. • Ensure adequate cardiac function before starting treatment with epirubicin. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Version 1.2 (November 2020) Page 1 of 7 Breast – Cyclophosphamide-Epirubicin-Paclitaxel (7 day) Haematological Prior to prescribing the following treatment criteria must be met on day one of treatment. Criteria Eligible Level Neutrophils equal to or more than 1x10 9/L Platelets equal to or more than 100x10 9/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophils and platelets then delay treatment for seven days.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Inhibition of Tumour Cell Growth by Hyperforin, a Novel Anticancer Drug from St
    Oncogene (2002) 21, 1242 ± 1250 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis Christoph M Schempp*,1, Vladimir Kirkin2, Birgit Simon-Haarhaus1, Astrid Kersten3, Judit Kiss1, Christian C Termeer1, Bernhard Gilb4, Thomas Kaufmann5, Christoph Borner5, Jonathan P Sleeman2 and Jan C Simon1 1Department of Dermatology, University of Freiburg, Hauptstrasse 7, D-79104 Freiburg, Germany; 2Institute of Genetics, Forschungszentrum Karlsruhe, PO Box 3640, D-76021 Karlsruhe, Germany; 3Institute of Pathology, University of Freiburg, Albertstrasse 19, D-79104 Freiburg, Germany; 4HWI Analytik, Hauptstrasse 28, 78106 Rheinzabern, Germany; 5Institute of Molecular Medicine, University of Freiburg, Breisacherstr. 66, D-79106 Freiburg, Germany Hyperforin is a plant derived antibiotic from St. John's Introduction wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by An exciting aspect of apoptosis is that it can be utilized induction of apoptosis. Hyperforin inhibited the growth of in the treatment of cancer (Revillard et al., 1998; various human and rat tumour cell lines in vivo, with IC50 Nicholson, 2000). Anticancer agents with dierent values between 3 ± 15 mM. Treatment of tumour cells with modes of action have been reported to trigger hyperforin resulted in a dose-dependent generation of apoptosis in chemosensitive cells (Hickman, 1992; apoptotic oligonucleosomes, typical DNA-laddering and Debatin, 1999). The process of apoptosis consists of apoptosis-speci®c morphological changes. In MT-450 dierent phases, including initiation, execution and mammary carcinoma cells hyperforin increased the activity degradation (Kroemer, 1997), and is activated by two of caspase-9 and caspase-3, and hyperforin-mediated major pathways.
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 Under The
    Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant Rule 14a-12 Of the Securities Exchange Act of 1934 Subject Company: Cell Therapeutics, Inc. Commission File No.: 001-12465 The following is a transcript of a presentation given by Cell Therapeutics, Inc. at its annual meeting of shareholders, held on June 20, 2003. Moderator: Jim Bianco Operator: Good day everyone and welcome to the Cell Therapeutics annual shareholder meeting. As a reminder, this call is being recorded. We’ll soon be going live to Seattle where the call will begin shortly. Please stand by. Jim Bianco: Welcome. My name is Jim Bianco. I’m the President and CEO of Cell Therapeutics. Welcome to our 2003 shareholders meeting. Our business meeting agenda today is to approve the minutes, elect the directors, and approve the equity incentive plan as well as the amendment to the employees stock purchase plan, and ratify the selection of E&Y as independent auditors. Mike Kennedy, the Secretary of the company, will act as secretary of this meeting, and George Pabst has been appointed inspector of elections to examine and count proxies and ballots. At the conclusion of the business portion of today’s meeting, members of management will present highlights from the past year and outline some of our future milestones and objectives for the next 12 to 18 months. At this time, I’d like to call the meeting to order. Let me begin by introducing our directors who are present today and let me start by saying that Dr.
    [Show full text]
  • Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
    G C A T T A C G G C A T genes Review Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation Reka Varnai 1,2, Leena M. Koskinen 3, Laura E. Mäntylä 3, Istvan Szabo 4,5, Liesel M. FitzGerald 6 and Csilla Sipeky 3,* 1 Department of Primary Health Care, University of Pécs, Rákóczi u 2, H-7623 Pécs, Hungary 2 Faculty of Health Sciences, Doctoral School of Health Sciences, University of Pécs, Vörösmarty u 4, H-7621 Pécs, Hungary 3 Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland 4 Institute of Sport Sciences and Physical Education, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 5 Faculty of Sciences, Doctoral School of Biology and Sportbiology, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia * Correspondence: csilla.sipeky@utu.fi Received: 17 June 2019; Accepted: 5 August 2019; Published: 8 August 2019 Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
    [Show full text]
  • Exosomes and Breast Cancer Drug Resistance Xingli Dong1,2, Xupeng Bai 2,3,Jieni2,3,Haozhang 4,Weiduan5, Peter Graham2,3 Andyongli 2,3,6
    Dong et al. Cell Death and Disease (2020) 11:987 https://doi.org/10.1038/s41419-020-03189-z Cell Death & Disease REVIEW ARTICLE Open Access Exosomes and breast cancer drug resistance Xingli Dong1,2, Xupeng Bai 2,3,JieNi2,3,HaoZhang 4,WeiDuan5, Peter Graham2,3 andYongLi 2,3,6 Abstract Drug resistance is a daunting challenge in the treatment of breast cancer (BC). Exosomes, as intercellular communicative vectors in the tumor microenvironment, play an important role in BC progression. With the in-depth understanding of tumor heterogeneity, an emerging role of exosomes in drug resistance has attracted extensive attention. The functional proteins or non-coding RNAs contained in exosomes secreted from tumor and stromal cells mediate drug resistance by regulating drug efflux and metabolism, pro-survival signaling, epithelial–mesenchymal transition, stem-like property, and tumor microenvironmental remodeling. In this review, we summarize the underlying associations between exosomes and drug resistance of BC and discuss the unique biogenesis of exosomes, the change of exosome cargo, and the pattern of release by BC cells in response to drug treatment. Moreover, we propose exosome as a candidate biomarker in predicting and monitoring the therapeutic drug response of BC and as a potential target or carrier to reverse the drug resistance of BC. ● Facts Tumor-derived exosomes mediate enhanced EMT and stem-like property of drug-resistant BC. ● ● Tumor-derived exosomes mediate the chemoresistance TME-derived exosomes mediate the tumor of BC by reducing the intracellular accumulation of microenvironmental remodeling that favors the drug resistance of BC. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; chemotherapeutic drugs and delivering functional ● cargos that activate pro-survival signaling and The exosome is proposed as a candidate biomarker in unchecked cell cycle progression.
    [Show full text]
  • A-Kinase Anchoring Protein 79/150 Scaffolds Transient Receptor Potential a 1 Phosphorylation and Sensitization by Metabotropic G
    www.nature.com/scientificreports OPEN A-Kinase Anchoring Protein 79/150 Scaffolds Transient Receptor Potential A 1 Phosphorylation and Received: 25 November 2016 Accepted: 5 April 2017 Sensitization by Metabotropic Published: xx xx xxxx Glutamate Receptor Activation Allison Doyle Brackley1, Ruben Gomez2, Kristi A. Guerrero2, Armen N. Akopian3, Marc J. Glucksman5, Junhui Du5, Susan M. Carlton6 & Nathaniel A. Jeske1,2,4 Mechanical pain serves as a base clinical symptom for many of the world’s most debilitating syndromes. Ion channels expressed by peripheral sensory neurons largely contribute to mechanical hypersensitivity. Transient Receptor Potential A 1 (TRPA1) is a ligand-gated ion channel that contributes to inflammatory mechanical hypersensitivity, yet little is known as to the post-translational mechanism behind its somatosensitization. Here, we utilize biochemical, electrophysiological, and behavioral measures to demonstrate that metabotropic glutamate receptor-induced sensitization of TRPA1 nociceptors stimulates targeted modification of the receptor. Type 1 mGluR5 activation increases TRPA1 receptor agonist sensitivity in an AKA-dependent manner. As a scaffolding protein for Protein Kinases A and C (PKA and PKC, respectively), AKAP facilitates phosphorylation and sensitization of TRPA1 in ex vivo sensory neuronal preparations. Furthermore, hyperalgesic priming of mechanical hypersensitivity requires both TRPA1 and AKAP. Collectively, these results identify a novel AKAP-mediated biochemical mechanism that increases TRPA1 sensitivity in peripheral sensory neurons, and likely contributes to persistent mechanical hypersensitivity. A-kinase Anchoring Protein 79/150 (AKAP) is a scaffolding protein expressed throughout neural tissues1. Importantly, AKAP facilitates post-translational modifications of plasma membrane receptors by kinases includ- ing Protein Kinase A (PKA) and Protein Kinase C (PKC2).
    [Show full text]
  • Psma-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
    PSMA-1-DOXORUBICIN CONJUGATES FOR TARGETED THERAPY OF PROSTATE CANCER by NATALIE WALKER Submitted in partial fulfillment of the requirements for the degree of Master of Science Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis of Natalie Walker candidate for the degree of Master of Science. Committee Chair Efstathios Karathanasis, PhD Committee Members James Basilion, PhD, Research Advisor Christopher Hoimes, DO Xinning Wang, PhD Date of Defense 14 January 2019 *We also certify that written approval has been obtained for any proprietary material contained therin. Contents List of Tables ..................................................................................................................... iv List of Figures ..................................................................................................................... v Abstract ............................................................................................................................... 1 Introduction ......................................................................................................................... 2 Table 1: Review of PSMA Expression in Nonprostate Malignancies. ................... 5 Figure 1: Outline of Structures of Three PSMA-1-Doxorubicin Prodrug Conjugates............................................................................................................... 8 Figure 2: Proposed Mechanism for Prodrug Release of
    [Show full text]
  • W O 2 11/ 28571Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date / 10 March 2011 (10.03.2011) W O 2 1 1/ 28 57 1 A l (51) International Patent Classification: (74) Agents: UDAL, Robert, P., Ph. D. et al; Morgan, Lewis A 43/02 (2006.01) & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US). (21) International Application Number: PCT/US20 10/046627 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 25 August 2010 (25.08.2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/238,787 1 September 2009 (01 .09.2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicant (for all designated States except US): TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. TAPESTRY PHARMACEUTICALS, INC. [US/US]; 6304 Spine Road, Unit A, Boulder, CO 80301 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (75) Inventors/ Applicants (for US only): MCCHESNEY, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, James, D.
    [Show full text]